Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Ben Y. Durkee

Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Journal of Clinical Oncology

English

Related publications

Pertuzumab in Human Epidermal Growth-Factor Receptor 2-Positive Breast Cancer: Clinical and Economic Considerations

International Journal of Women's Health

English

Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer

Expert Opinion on Biological Therapy

Drug Discovery

Clinical Biochemistry

Pharmacology

2013

English

Expression of Growth Factor Receptor Family Before and After Targeted Therapy in Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Tissues

Korean Journal of Clinical Oncology

2015

English

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab With Taxane for Human Epidermal Growth Factor Receptor 2–positive Advanced Breast Cancer: Final Results From MARIANNE

English

Efficacy and Safety of Palbociclib Plus Endocrine Therapy in North American Women With Hormone Receptor‐positive/Human Epidermal Growth Factor Receptor 2‐negative Metastatic Breast Cancer

English

Patients’ Preferences for Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Treatments in Japan

English

Delaying Chemotherapy in the Treatment of Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Clinical Medicine Insights: Oncology

Oncology

2015

English

Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Is Associated With Indigenous American Ancestry in Latin American Women

Cancer Research

Oncology

2020

English

FEN1 Knockdown Improves Trastuzumab Sensitivity in Human Epidermal Growth Factor 2‑positive Breast Cancer Cells

Experimental and Therapeutic Medicine

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Ben Y. Durkee

Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Related publications

Pertuzumab in Human Epidermal Growth-Factor Receptor 2-Positive Breast Cancer: Clinical and Economic Considerations

Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer

Expression of Growth Factor Receptor Family Before and After Targeted Therapy in Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Tissues

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab With Taxane for Human Epidermal Growth Factor Receptor 2–positive Advanced Breast Cancer: Final Results From MARIANNE

Efficacy and Safety of Palbociclib Plus Endocrine Therapy in North American Women With Hormone Receptor‐positive/Human Epidermal Growth Factor Receptor 2‐negative Metastatic Breast Cancer

Patients’ Preferences for Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Treatments in Japan

Delaying Chemotherapy in the Treatment of Hormone Receptor&ndash;Positive, Human Epidermal Growth Factor Receptor 2&ndash;Negative Advanced Breast Cancer

Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Is Associated With Indigenous American Ancestry in Latin American Women

FEN1 Knockdown Improves Trastuzumab Sensitivity in Human Epidermal Growth Factor 2‑positive Breast Cancer Cells

Delaying Chemotherapy in the Treatment of Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer